In the phase 1 portion of the study, the primary objectives are to assess the safety, tolerability, and dose-limiting toxicities (DLTs) and to determine a recommended phase 2 dose regimen (RP2DR) of REGN5459 as monotherapy in patients with relapsed or refractory multiple myeloma (MM) who have exhausted all therapeutic options that are expected to provide meaningful clinical benefit.
SparkCures ID | 1078 |
---|---|
Trial Phase | Phase 1/2 |
Enrollment | 43 Patients |
Treatments | |
Tags | |
Trial Sponsors |
|
NCT Identifier |
|
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
Key Inclusion Criteria:
d. Serum creatinine clearance by Cockcroft-Gault >30 mL/min
Key Exclusion Criteria:
NOTE: Other protocol defined Inclusion/Exclusion Criteria apply.
Please visit the ClinicalTrials.gov page for historical site information.
View Centers